232 related articles for article (PubMed ID: 19351848)
21. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.
Tararova ND; Narizhneva N; Krivokrisenko V; Gudkov AV; Gurova KV
Prostate; 2007 Dec; 67(16):1801-15. PubMed ID: 17935158
[TBL] [Abstract][Full Text] [Related]
22. Androgen deprivation increases p300 expression in prostate cancer cells.
Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
24. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
25. Expression of androgen receptor is negatively regulated by p53.
Alimirah F; Panchanathan R; Chen J; Zhang X; Ho SM; Choubey D
Neoplasia; 2007 Dec; 9(12):1152-9. PubMed ID: 18084622
[TBL] [Abstract][Full Text] [Related]
26. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2.
Zheng C; Yinghao S; Li J
Med Oncol; 2012 Jun; 29(2):815-22. PubMed ID: 21487968
[TBL] [Abstract][Full Text] [Related]
27. Expression of GnRH type II is regulated by the androgen receptor in prostate cancer.
Darby S; Stockley J; Khan MM; Robson CN; Leung HY; Gnanapragasam VJ
Endocr Relat Cancer; 2007 Sep; 14(3):613-24. PubMed ID: 17914092
[TBL] [Abstract][Full Text] [Related]
28. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.
Ma S; Chan YP; Kwan PS; Lee TK; Yan M; Tang KH; Ling MT; Vielkind JR; Guan XY; Chan KW
Cancer Res; 2011 Jan; 71(2):583-92. PubMed ID: 21224345
[TBL] [Abstract][Full Text] [Related]
30. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
31. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.
Cai C; Hsieh CL; Omwancha J; Zheng Z; Chen SY; Baert JL; Shemshedini L
Mol Endocrinol; 2007 Aug; 21(8):1835-46. PubMed ID: 17505060
[TBL] [Abstract][Full Text] [Related]
32. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
Chuu CP; Hiipakka RA; Fukuchi J; Kokontis JM; Liao S
Cancer Res; 2005 Mar; 65(6):2082-4. PubMed ID: 15781616
[TBL] [Abstract][Full Text] [Related]
33. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
34. The PPARĪ³ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Moss PE; Lyles BE; Stewart LV
Exp Cell Res; 2010 Dec; 316(20):3478-88. PubMed ID: 20932825
[TBL] [Abstract][Full Text] [Related]
35. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R
Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697
[TBL] [Abstract][Full Text] [Related]
36. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
37. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
39. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate.
Wang LG; Liu XM; Chiao JW
Carcinogenesis; 2006 Oct; 27(10):2124-32. PubMed ID: 16704988
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
Pinto JT; Sinha R; Papp K; Facompre ND; Desai D; El-Bayoumy K
Int J Cancer; 2007 Apr; 120(7):1410-7. PubMed ID: 17205524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
